Skip to main content
RUA LIFE SCIENCES PLC logo

RUA LIFE SCIENCES PLC — Investor Relations & Filings

Ticker · RUA ISIN · GB0033360586 LEI · 213800BMVB22PVOJ9Z28 IL Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2023-06-07 Earnings Release
Country GB United Kingdom
Listing IL RUA

About RUA LIFE SCIENCES PLC

https://rualifesciences.com/

RUA Life Sciences is a medical device group focused on the application of its proprietary long-term implantable polymer, Elast-Eon™, a biostable polyurethane. The company operates through four integrated businesses to develop, manufacture, and license medical device solutions. RUA Biomaterials is responsible for licensing the Elast-Eon™ technology. RUA Medical provides end-to-end contract development and manufacturing services, specializing in implantable fabrics. RUA Vascular develops large-bore, polymer-sealed vascular grafts and soft tissue patches. RUA Structural Heart is engaged in the development of next-generation tri-leaflet polymeric heart valves. The group's collective mission is to improve patient outcomes by enabling and enhancing medical devices through its advanced polymer technology.

Recent filings

Filing Released Lang Actions
Trading Update
Earnings Release Classification · 1% confidence The document is titled 'March 2023 Full Year Trading Update' and provides unaudited financial highlights (revenue growth, profit margins, loss before tax, cash balance) for the 12 months ended 31 March 2023. It explicitly states that the audited final results are expected mid-July 2023. This structure—a preliminary update on financial performance for a period, often released before the full statutory report—is characteristic of an Earnings Release (ER). It contains key financial figures but is not the comprehensive Annual Report (10-K) or the detailed Management Discussion & Analysis (MDA). The presence of the RNS Number and the LSE footer confirms it is a regulatory announcement, but the content is focused on results, making ER the most specific fit over the general RNS. FY 2023
2023-06-07 English
Distribution Agreement with Corcym
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated January 25, 2023. It announces a significant business event: the signing of a 'Distribution Agreement with Corcym' for RUA Life Sciences' vascular grafts. The text explicitly states, 'The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation...'. This structure—a brief announcement of material, non-public information released via the RNS system—is characteristic of a general regulatory news service release. Since the content is a specific business development (a distribution agreement/partnership) and not a standard financial report (10-K, IR, ER), nor a director dealing (DIRS), nor a proxy statement (PSI), it fits best under the general regulatory announcement category, RNS, which serves as the fallback for specific regulatory news that isn't covered by other codes.
2023-01-25 English
Science Journal Publication
Regulatory Filings Classification · 1% confidence The document is a short announcement (3198 characters) distributed via RNS, specifically mentioning 'RNS REACH' and stating that 'Reach is a non-regulatory news service.' The content announces that a detailed scientific paper about the company's graft technology has been accepted for publication in the Journal of Surgical Research and provides a link to it. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement that informs about the publication of external material, rather than being the report itself, should be classified as a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Since this is an announcement about a scientific publication, RPA is a strong candidate, but given the context of RNS distribution and the explicit mention of 'Reach' as a non-regulatory news service, the general fallback category 'RNS' is also highly appropriate for non-core regulatory updates. However, since the core action is announcing the publication of a paper, RPA fits the description of announcing the release of information better than the general RNS fallback, although RNS is also plausible due to the distribution channel. Given the explicit mention of the publication being available, RPA is the most precise fit among the specific options.
2022-12-22 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document explicitly states it is an announcement regarding a 'Director Dealing' involving the Chief Financial Officer, Lachlan Smith, purchasing ordinary shares. It details the transaction date (14 December 2022), price, volume, and the resulting holding. This directly corresponds to the definition of Director's Dealing (insider trades). The presence of 'RNS Number' and the closing statement referencing the London Stock Exchange and the Financial Conduct Authority confirms it is a regulatory filing of this specific nature. The appropriate code is DIRS.
2022-12-14 English
Grant of Share Options
Remuneration Information Classification · 1% confidence The document is an official announcement disseminated via RNS (RNS Number: 5868J) on December 13, 2022. The content details the 'Grant of EMI Share Options' to executive Directors (PDMRs) and includes specific transaction tables required for insider dealing disclosures (Section 1, 2, 3). This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it is an RNS announcement, the specific nature of the content (PDMR transaction details) makes DIRS the most accurate classification over the general RNS fallback.
2022-12-13 English
Interim results
Earnings Release Classification · 1% confidence The document explicitly states it announces the 'unaudited interim results for the six months ended 30 September 2022'. It provides key financial highlights (revenues, gross profit, loss reduction, cash position) and detailed segmental performance updates (Biomaterials, Contract Manufacturing, Vascular, Structural Heart). This structure and content clearly identify it as a comprehensive financial report covering a period shorter than a year. This matches the definition for an Interim / Quarterly Report (IR). Although it is distributed via RNS, the content itself is the full report, not just an announcement of the report's publication (RPA/RNS). H1 2023
2022-12-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.